LIfT BioSciences Ltd, a developer of neutrophil immuno-therapies, has appointed Mark A Exley as chief scientific officer as the company prepares for clinical trials of its first-in-class immuno-modulator. LIfT’s allogeneic neutrophil-based cell therapy is designed to rejuvenate immune competence and overcome treatment resistance in solid tumours. Dr Exley brings over 30 years of experience from discovery to late-stage clinical trials in industry and academia. Most recently, he was CSO of Imvax Inc and prior to that was vice president of immunology at the predecessor company of MiNK Therapeutics, where he is still a scientific advisory board member. Dr Exley holds a PhD in cell biology from the Institute of Cancer Research, UK and has held several academic roles at Harvard Medical School, US and the University of Manchester, UK.
LIfT BioSciences announced the appointment on 7 April 2025.
Copyright 2025 Evernow Publishing Ltd.